SEARCH

SEARCH BY CITATION

References

  • 1
    Hedner U, Erhardtsen E. Hemostatic disorders in liver diseases. In: SchiffER et al., eds. Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins, 2003: 625636.
  • 2
    Francis RB, Jr., Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984; 14: 460465.
  • 3
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. HEPATOLOGY 2003; 38: 230237.
  • 4
    Bosch J, D'Amico G, García-Pagán JC. Portal hypertension. In: SchiffER et al., eds. Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins, 2003: 429486.
  • 5
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001; 33: 464470.
  • 6
    Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. HEPATOLOGY 2005; 41: 553558.
  • 7
    Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 415.
  • 8
    Erlinger S, Benhamou P. Cirrhosis: clinical aspects. In: McIntyreN et al., eds. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1991: 380390.
  • 9
    Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J Clin Invest 1996; 98: 863874.
  • 10
    Ordinas A, Escolar G, Cirera I, Vinas M, Cobo F, Bosch J, et al. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. HEPATOLOGY 1996; 24: 11371142.
  • 11
    Burroughs AK, Bosch J. Clinical manifestations and management of bleeding episodes in cirrhotics. In: McIntyreN, et al., eds. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1991: 408-;425.
  • 12
    Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez AJ, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127: 11231130.
  • 13
    Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131139.